Article: Lexicon Genetics Announces Milestone in LexVision(TM) Collaboration With Bristol-Myers Squibb.

THE WOODLANDS, Texas, Jan. 8 /PRNewswire/ --

Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has delivered to Bristol-Myers Squibb Company (NYSE: BMY) its first installment of the LexVision (TM) database containing gene function information for potential new drug targets. This installment, which was delivered prior to year-end 2000, triggered the initial quarterly payment from Bristol-Myers Squibb for its first year of access to LexVision.

"We are very pleased with the data that Lexicon's technology has generated for LexVision," stated James R. Piggott, Ph.D., Senior Vice President of Pharmaceutical Biology at Lexicon Genetics. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!